Importance of monitoring and early switch to second generation tyrosine kinase inhibitors for the prognosis of patients with chronic myeloid leukemia with imatinib resistance or intolerance
Abstract:Imatinib mesylate was the first BCR-ABL-target agent approved for the treatment of
chronic myeloid leukemia. Although most patients respond well to imatinib therapy,
the literature shows that one third develops resistance or intolerance. The timing of
second-line treatment after failure of initial treatment may have a significant
impact on long-term outcome. Thus, appropriate monitoring to identify resistance
and/or intolerance is crucial to early intervention with second generation tyrosine
kinase inhibitors … Show more
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.